Home Search

gene therapy - search results

If you're not happy with the results, please do another search
treat osteogenesis imperfecta

Stem cell & gene therapy to treat osteogenesis imperfecta: hype or hope

Pascale V Guillot from University College London, Elizabeth Garrett Anderson Institute for Women’s Health, explains stem cell and gene therapy to treat osteogenesis imperfecta, but is this hype or hope?
gene therapy field

What are the challenges surrounding gene therapy today?

Dr Jen Vanderhoven, Director, National Horizons Centre, Teesside University, sheds some light on how the gene therapy field can progress in the face of funding challenges and skills shortages.
restore eyesight, gene therapy

Scientists successfully use gene therapy to restore eyesight 

Scientists in France have partially restored the eyesight of a blind man, using gene therapy - he is now able to identify blurry shapes.
new gene therapy, OPA1

New gene therapy for eye disease developed in Ireland

Scientists from Trinity College Dublin have developed a new gene therapy for an eye disease that leads to progressive loss of vision.
diabetic retinopathy

Repurposing FDA-approved medicines and gene therapy to combat diabetic retinopathy

Lalit Singh Pukhrambam, PhD, and Ahmed S Ibrahim, PhD from Wayne State University School of Medicine in the U.S. focus here on the importance of combating diabetic retinopathy.
human gene therapy

AAV: From almost a virus to an awesome vector for human gene therapy

Dr. Arun Srivastava, George H. Kitzman Professor of Genetics, from the University of Florida describes the rationale and strategies for the development of next generation (NextGen), generation X (GenX) and optimised (Opt) recombinant AAV vectors for human gene therapy Recombinant AAV vectors have been, or are currently being, used in...
eye health

Eye health: Testing the safety of stem cell therapy for age-related macular degeneration

Kapil Bharti, PhD, Senior Investigator and Head of the Ocular and Stem Cell Translational Research Section at the National Eye Institute (NEI), explains testing the safety of a stem cell therapy for age-related macular degeneration in this special focus on eye health.
Duchenne muscular dystrophy

Duchenne muscular dystrophy: A test case for gene-targeted therapy development in rare disease

Laura Hagerty, PhD, Scientific Portfolio Director at the Muscular Dystrophy Association, highlights strategies for gene correction to treat Duchenne muscular dystrophy.
next generation cancer immunotherapy

Nano DDS technology contributes to next-generation cancer immunotherapy

Dr Takashi Nakamura from Hokkaido University challenges the potential of nano-tech based drug delivery system (Nano DDS) in the development of next-generation cancer immunotherapy.
ID 63640029 © Milkovasa | Dreamstime.com

The regenerating spiny mouse and its potential for human therapy discovery

Discovering cures for human diseases or how to recover from damage or trauma to tissues is the fundamental goal of medical researchers, but it is a daunting task. Nevertheless, recent studies have shown the remarkable potential of the spiny mouse in addressing these crucial issues
spinal muscular atrophy

Spinal muscular atrophy (SMA) – research from gene and modifiers to therapy

The fascinating research of Professor Brunhilde Wirth is placed under the spotlight, concerning her work in the field of disease-causing genes, modifier pathways and pathomechanisms of neuromuscular disorders, focussing on spinal muscular atrophy (SMA)

New concepts for the pathogenesis and asthma therapy

Prof Dr. Michael Roth, University Hospital Basel looks at how asthma therapy can reduce the effects of airway wall remodelling
individualised multimodal immunotherapy, brain cancer

Individualised Multimodal Immunotherapy beyond personalised medicine for brain cancer

Stefaan Van Gool, MD, PhD brings to light the important role of Individualised Multimodal Immunotherapy in improving the survival of brain cancer.
Osteogenesis Imperfecta, bone cell function

The future of living with Osteogenesis Imperfecta

CEO of Brittle Bone Society Patricia Osborne, revisits aspects of the condition and shares what is known around current medical research and treatments, speaking to experts attached to the Charity.
oncolytic virus, fraunhofer institute

TheraVision: An oncolytic virus platform technology for a personalised virus-immunotherapy

Prof Dr Susanne M Bailer, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, explains the possibilities of an oncolytic virus platform technology.
brittle bone disease, exosome therapy

Exosome therapy for brittle bone disease

Pascale V Guillot, Associate Professor at University College London, investigates the possibility of exosome therapy for those living with brittle bone disease.
metastatic breast cancer

Prospects for minimally invasive and optimally effective cancer immunotherapy

Here, Professor of Biochemistry, Microbiology & Immunology at the University of Saskatchewan, Peter Betscher, explains how he is dedicated towards realising Robert North’s vision.
mutated als gene

New gene-silencing drug could help with ALS

New research suggests that in suppressing a mutated ALS gene, it may be possible to delay to onset of symptoms.
brain tumour patients

Getting personal in brain tumour therapy: Matching therapies to patients

Sean E. Lawler PhD from Brown University Cancer Center, an experienced scientist in the brain tumour field
creatine deficiency, genetic treatment

Genetic disease treatment research for creatine deficiency

Professor Olivier Braissant, believes there is hope for the treatment of creatine deficiency thanks to new genetic disease research - here, he tells us all about the recent developments.

Follow Open Access Government